 Xeris Biopharma Holdings Inc NASDAQ:XERS has announced positive topline results from its Phase 1 study of subcutaneous SC levothyroxine XP-8121 in healthy adult volunteers. Using its XeriSol technology, the company is developing a novel formulation of levothyroxine sodium SC injection to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. 